432 related articles for article (PubMed ID: 28413992)
1. Screening and Elucidation of Selected Natural Compounds for Anti- Alzheimer's Potential Targeting BACE-1 Enzyme: A Case Computational Study.
Ahmad SS; Akhtar S; Danish Rizvi SM; Kamal MA; Sayeed U; Khan MKA; Siddiqui MH; Arif JM
Curr Comput Aided Drug Des; 2017 Nov; 13(4):311-318. PubMed ID: 28413992
[TBL] [Abstract][Full Text] [Related]
2. Polymethoxyflavones: Novel β-Secretase (BACE1) Inhibitors from Citrus Peels.
Youn K; Yu Y; Lee J; Jeong WS; Ho CT; Jun M
Nutrients; 2017 Sep; 9(9):. PubMed ID: 28869548
[TBL] [Abstract][Full Text] [Related]
3. BACE1 molecular docking and anti-Alzheimer's disease activities of ginsenosides.
Choi RJ; Roy A; Jung HJ; Ali MY; Min BS; Park CH; Yokozawa T; Fan TP; Choi JS; Jung HA
J Ethnopharmacol; 2016 Aug; 190():219-30. PubMed ID: 27275774
[TBL] [Abstract][Full Text] [Related]
4. Conformational transition in the substrate binding domain of β-secretase exploited by NMA and its implication in inhibitor recognition: BACE1-myricetin a case study.
Chakraborty S; Kumar S; Basu S
Neurochem Int; 2011 Jul; 58(8):914-23. PubMed ID: 21354237
[TBL] [Abstract][Full Text] [Related]
5. Flavonols and flavones as BACE-1 inhibitors: structure-activity relationship in cell-free, cell-based and in silico studies reveal novel pharmacophore features.
Shimmyo Y; Kihara T; Akaike A; Niidome T; Sugimoto H
Biochim Biophys Acta; 2008 May; 1780(5):819-25. PubMed ID: 18295609
[TBL] [Abstract][Full Text] [Related]
6. Molecular docking based virtual screening of natural compounds as potential BACE1 inhibitors: 3D QSAR pharmacophore mapping and molecular dynamics analysis.
Kumar A; Roy S; Tripathi S; Sharma A
J Biomol Struct Dyn; 2016; 34(2):239-49. PubMed ID: 25707809
[TBL] [Abstract][Full Text] [Related]
7. Flavanone glycosides inhibit β-site amyloid precursor protein cleaving enzyme 1 and cholinesterase and reduce Aβ aggregation in the amyloidogenic pathway.
Ali MY; Jannat S; Edraki N; Das S; Chang WK; Kim HC; Park SK; Chang MS
Chem Biol Interact; 2019 Aug; 309():108707. PubMed ID: 31194956
[TBL] [Abstract][Full Text] [Related]
8. Molecular insights into the inhibitory mechanism of bi-functional bis-tryptoline triazole against β-secretase (BACE1) enzyme.
Narang SS; Goyal D; Goyal B
Amino Acids; 2019 Nov; 51(10-12):1593-1607. PubMed ID: 31654211
[TBL] [Abstract][Full Text] [Related]
9. Study on the active mechanism of β-secretase inhibitors by molecular simulations.
Tian YL; Lv M; Li JJ; Xu T; Zhai HL; Zhang XY
Eur J Pharm Sci; 2015 Aug; 76():138-48. PubMed ID: 25965961
[TBL] [Abstract][Full Text] [Related]
10. Dynamic Simulation, Docking and DFT Studies Applied to a Set of Anti-Acetylcholinesterase Inhibitors in the enzyme β-Secretase (BACE-1): An Important Therapeutic Target in Alzheimer`s disease.
Silva-Junior EF; Barcellos Franca PH; Quintans-Junior LJ; Mendonca-Junior FJB; Scotti L; Scotti MT; de Aquino TM; de Araujo-Junior JX
Curr Comput Aided Drug Des; 2017 Nov; 13(4):266-274. PubMed ID: 28382866
[TBL] [Abstract][Full Text] [Related]
11. Target specific proteochemometric model development for BACE1 - protein flexibility and structural water are critical in virtual screening.
Manoharan P; Chennoju K; Ghoshal N
Mol Biosyst; 2015 Jul; 11(7):1955-72. PubMed ID: 25927726
[TBL] [Abstract][Full Text] [Related]
12. A PM7 dynamic residue-ligand interactions energy landscape of the BACE1 inhibitory pathway by hydroxyethylamine compounds. Part I: The flap closure process.
Gueto-Tettay C; Martinez-Consuegra A; Zuchniarz J; Gueto-Tettay LR; Drosos-Ramírez JC
J Mol Graph Model; 2017 Sep; 76():274-288. PubMed ID: 28746905
[TBL] [Abstract][Full Text] [Related]
13. Computational modelling of potent β-secretase (BACE1) inhibitors towards Alzheimer's disease treatment.
Ugbaja SC; Sanusi ZK; Appiah-Kubi P; Lawal MM; Kumalo HM
Biophys Chem; 2021 Mar; 270():106536. PubMed ID: 33387910
[TBL] [Abstract][Full Text] [Related]
14. Computational analysis of BACE1-ligand complex crystal structures and linear discriminant analysis for identification of BACE1 inhibitors with anti P-glycoprotein binding property.
Manoharan P; Chennoju K; Ghoshal N
J Biomol Struct Dyn; 2018 Jan; 36(1):262-276. PubMed ID: 28081663
[TBL] [Abstract][Full Text] [Related]
15. Acylguanidine-BACE1 complex: Insights of intermolecular interactions and dynamics.
Saravanan K; Kumaradhas P
J Theor Biol; 2019 Mar; 464():33-49. PubMed ID: 30571961
[TBL] [Abstract][Full Text] [Related]
16. Structure-Based Survey of the Binding Modes of BACE1 Inhibitors.
Hu H; Chen Z; Xu X; Xu Y
ACS Chem Neurosci; 2019 Feb; 10(2):880-889. PubMed ID: 30540177
[TBL] [Abstract][Full Text] [Related]
17. Novel small molecule therapeutic agents for Alzheimer disease: Focusing on BACE1 and multi-target directed ligands.
Iraji A; Khoshneviszadeh M; Firuzi O; Khoshneviszadeh M; Edraki N
Bioorg Chem; 2020 Apr; 97():103649. PubMed ID: 32101780
[TBL] [Abstract][Full Text] [Related]
18. Flavonoids as BACE1 inhibitors: QSAR modelling, screening and in vitro evaluation.
Das S; Majumder T; Sarkar A; Mukherjee P; Basu S
Int J Biol Macromol; 2020 Dec; 165(Pt A):1323-1330. PubMed ID: 33010267
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of BACE1 Activity by a DNA Aptamer in an Alzheimer's Disease Cell Model.
Liang H; Shi Y; Kou Z; Peng Y; Chen W; Li X; Li S; Wang Y; Wang F; Zhang X
PLoS One; 2015; 10(10):e0140733. PubMed ID: 26473367
[TBL] [Abstract][Full Text] [Related]
20. Investigation of intermolecular interactions and stability of verubecestat in the active site of BACE1: Development of first model from QM/MM-based charge density and MD analysis.
Saravanan K; Sivanandam M; Hunday G; Mathiyalagan L; Kumaradhas P
J Biomol Struct Dyn; 2019 Jun; 37(9):2339-2354. PubMed ID: 30044206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
